News

Encellin Closes $5.9M Seed Financing

Encellin, a personalized regenerative medicine biotech company, founded at the University of California San Francisco (UCSF), and developing novel cell-based approaches to deliver sustained therapies with a single implant, today announced the closing of a $5.9M Seed financing round. The round was...

UCSF Health Awards Returns for 3rd Year and Includes Life Sciences Awards

Preview Video Link for the Award Show can be viewed here

Sonoma Biotherapeutics Raises $265M

Biotech company Sonoma Biotherapeutics has raised $265 million in new funding, the company announced Wednesday. The funding will be used to advance its programs aiming to treat autoimmune and inflammatory conditions such as rheumatoid arthritis and type 1 diabetes.

Epygenix Therapeutics to Proceed With Trial for the Treatment of Dravet Syndrome

Epygenix Therapeutics, a clinical-stage biopharmaceutical company focused on rare and intractable genetic epilepsy that uses UCSF technology developed by Dr. Scott Baraban, is pleased to announce that the company's ARGUS trial with EPX-100 (Clemizole Hydrochloride) in patients with Dravet syndrome...

RxSight sets terms for $125 million IPO

RxSight, a commercial med-tech company based on UCSF post-cataract intraocular lens technology, announced terms for its IPO on Monday. The company plans to raise $125 million by offering 7.4 million shares at a price range of $16 to $18.  MORE

Erasca Announces Closing of Initial Public Offering

Erasca, Inc., a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the closing of its initial public offering of 21,562,500 shares of common stock, which includes...

Device taps brain waves to help paralyzed man communicate

University of California, San Francisco, neurosurgeon Dr. Edward Chang performs surgery at UCSF. In a medical first, researchers, led by Chang, harnessed the brain waves of a man paralyzed and unable to speak for 15 years - and turned what he intended to say into sentences on a computer screen. ...

Erasca to be valued at up to $1.8 billion

Erasca Inc. disclosed that it has set terms of its initial public offering, in which the California-based pre-revenue, clinical-stage precision oncology company could be valued up to $1.84 billion. University of California's researcher, Kevan Shokat PhD., is a lead contributor to Erasca's cancer...

UCSF and PrinterPrezz Collaborate to Produce a Layer of Personal Protection

Dr. Alessandro Villa, an Associate Professor at UC San Francisco, and PrinterPrezz, a trailblazer in combining polymer and metal 3D printing, nanotechnologies and surgical expertise to design and manufacture next generation medical devices, today announced a partnership to produce “The Cupola,” a...

The Next Pandemic?

Even with powerful vaccines in hand and the coronavirus waning across most of the United States, there’s still an urgent need for drugs to treat COVID-19 — and that could lay the foundation for the next generation of therapies for pandemics, say Bay Area scientists conducting such research. MORE